JP2016516026A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516026A5
JP2016516026A5 JP2015562529A JP2015562529A JP2016516026A5 JP 2016516026 A5 JP2016516026 A5 JP 2016516026A5 JP 2015562529 A JP2015562529 A JP 2015562529A JP 2015562529 A JP2015562529 A JP 2015562529A JP 2016516026 A5 JP2016516026 A5 JP 2016516026A5
Authority
JP
Japan
Prior art keywords
alkyl
ethoxy
acetamide
oxo
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015562529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/059817 external-priority patent/WO2014141187A1/en
Publication of JP2016516026A publication Critical patent/JP2016516026A/ja
Publication of JP2016516026A5 publication Critical patent/JP2016516026A5/ja
Pending legal-status Critical Current

Links

JP2015562529A 2013-03-15 2014-03-14 Rearrangedduringtransfection(ret)キナーゼ阻害剤としてのピリジン誘導体 Pending JP2016516026A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/072683 2013-03-15
CN2013072683 2013-03-15
CNPCT/CN2013/090059 2013-12-20
CN2013090059 2013-12-20
CNPCT/CN2014/072449 2014-02-24
CN2014072449 2014-02-24
PCT/IB2014/059817 WO2014141187A1 (en) 2013-03-15 2014-03-14 Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2016516026A JP2016516026A (ja) 2016-06-02
JP2016516026A5 true JP2016516026A5 (cg-RX-API-DMAC7.html) 2017-04-13

Family

ID=50390154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562529A Pending JP2016516026A (ja) 2013-03-15 2014-03-14 Rearrangedduringtransfection(ret)キナーゼ阻害剤としてのピリジン誘導体

Country Status (33)

Country Link
US (2) US9382238B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970191B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016516026A (cg-RX-API-DMAC7.html)
CN (1) CN105051027A (cg-RX-API-DMAC7.html)
AU (1) AU2014229233B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023618A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905627A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015002514A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150490A (cg-RX-API-DMAC7.html)
CY (1) CY1118730T1 (cg-RX-API-DMAC7.html)
DK (1) DK2970191T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000244A (cg-RX-API-DMAC7.html)
EA (1) EA029296B1 (cg-RX-API-DMAC7.html)
ES (1) ES2616655T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170363T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033423T2 (cg-RX-API-DMAC7.html)
IL (1) IL241161A0 (cg-RX-API-DMAC7.html)
LT (1) LT2970191T (cg-RX-API-DMAC7.html)
ME (1) ME02664B (cg-RX-API-DMAC7.html)
MX (1) MX2015012286A (cg-RX-API-DMAC7.html)
NZ (1) NZ628388A (cg-RX-API-DMAC7.html)
PE (1) PE20151538A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015502044A1 (cg-RX-API-DMAC7.html)
PL (1) PL2970191T3 (cg-RX-API-DMAC7.html)
PT (1) PT2970191T (cg-RX-API-DMAC7.html)
RS (1) RS55710B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201506695UA (cg-RX-API-DMAC7.html)
SI (1) SI2970191T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700152T1 (cg-RX-API-DMAC7.html)
TW (1) TW201524958A (cg-RX-API-DMAC7.html)
UA (1) UA115264C2 (cg-RX-API-DMAC7.html)
UY (1) UY35465A (cg-RX-API-DMAC7.html)
WO (1) WO2014141187A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3205654T (pt) 2010-05-20 2019-04-22 Array Biopharma Inc Compostos macrocíclicos como inibidores de cinases trk
AU2015313894A1 (en) * 2014-09-08 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
WO2016037578A1 (en) 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Novel compounds as rearranged during transfection (ret) inhibitors
EP3517526B1 (en) * 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
US20190142868A1 (en) 2016-05-13 2019-05-16 Instituto de Medicina Moleccular Methods of treating diseases associated with ilc3 cells
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3624802A1 (en) 2017-05-15 2020-03-25 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) * 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CN109096264B (zh) * 2018-08-28 2019-08-23 山东理工职业学院 Ret抑制剂及其制备方法、组合物和用途
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
AU2020257301B2 (en) 2019-04-18 2025-10-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
CN117903123A (zh) * 2020-02-20 2024-04-19 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
AR121914A1 (es) * 2020-04-27 2022-07-20 Lilly Co Eli Compuestos útiles para inhibir la quinasa ret
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN115803316B (zh) * 2020-07-23 2024-12-06 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
IL302542A (en) * 2020-11-06 2023-07-01 Lilly Co Eli Pyrazole derivatives as RET KINASE inhibitors
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー.アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳-脂肪回路を介してilc2および肥満度を制御する神経-間葉単位
CN115626880B (zh) * 2022-11-15 2023-11-14 常州大学 3-硝基-5-氰基三氟甲苯的合成方法
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法
EP4650002A1 (en) * 2024-05-15 2025-11-19 Ludwig-Maximilians-Universität Aniline-based modulators of the nuclear receptor tlx (nr2e1)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507329A (ja) 1999-08-12 2003-02-25 フアルマシア・イタリア・エツセ・ピー・アー 3(5)−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用
JP2004517840A (ja) * 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008046802A1 (en) 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
CA2701959C (en) * 2006-11-15 2016-01-05 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
KR20120059558A (ko) * 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento

Similar Documents

Publication Publication Date Title
JP2016516026A5 (cg-RX-API-DMAC7.html)
ME02664B (me) Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze
JP2016528201A5 (cg-RX-API-DMAC7.html)
JP2017538750A5 (cg-RX-API-DMAC7.html)
JP2018519323A5 (cg-RX-API-DMAC7.html)
JP2013510859A5 (cg-RX-API-DMAC7.html)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
JP2007519694A5 (cg-RX-API-DMAC7.html)
JP2016519685A5 (cg-RX-API-DMAC7.html)
JP2014526500A5 (cg-RX-API-DMAC7.html)
JP2016536364A5 (cg-RX-API-DMAC7.html)
RU2017125520A (ru) Соединения, ингибирующие parg
JP2016536363A5 (cg-RX-API-DMAC7.html)
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
RU2013112122A (ru) Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
HRP20130969T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
JP2017512786A5 (cg-RX-API-DMAC7.html)
HRP20130967T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
PE20191792A1 (es) Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
HRP20200606T1 (hr) Derivati fenila kao agonisti kanabinoidnog receptora 2
JP2013525262A5 (cg-RX-API-DMAC7.html)
RU2013130879A (ru) Производные оксазолилметилового эфира в качестве агонистов рецептора alx
RU2018103198A (ru) Новые соединения циклического n-карбоксамида, применяемые в качестве гербицидов